Amryt Pharma

Aegerion deal unlocks global opportunity

  • Sectors : Pharma and healthcare
  • Companies : Amryt Pharma

Ratings and price correct at time of issue.

  • Amryt Pharma

    Closing Price: 122.5p

  • RATING 29/07/19



The Aegerion deal is clearly transformational; however, of greater interest, is that value accretion for shareholders is just beginning. The enlarged group has a global platform to commercialise a very attractive pipeline. Amryt can also extract multiple synergies due to the complementary fit of the commercial teams, with its deep knowledge of Aegerion’s pipeline providing confidence on execution. We think the enlarged group has scope to de-lever to 2.1x net debt/EBITDA by 2021 and see a logical pathway to the stock more than doubling over the next couple of years.

Download full report with analyst certification and important disclosures

Nov 14 2019, 07:10 GMT